Long-term administration of recombinant canstatin prevents adverse cardiac remodeling after myocardial infarction

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Molecular Biology

Background:

• Myocardial infarction (MI) is a major global cause of death.
• Adverse cardiac remodeling, including hypertrophy and fibrosis, leads to heart failure post-MI.
• Canstatin, a collagen fragment, previously showed anti-remodeling effects in a cardiac hypertrophy model.

Purpose of the Study:

• To investigate the cardioprotective effects of long-term recombinant canstatin administration in a rat model of myocardial infarction.
• To assess canstatin's impact on adverse cardiac remodeling and cardiac function following MI.

Main Methods:

• Male Wistar rats underwent ligation of the left anterior descending artery to induce MI.
• Recombinant mouse canstatin (20 μg/kg/day) was administered intraperitoneally for 28 days.
• Evaluated survival rates, left ventricular dimensions and function, scar integrity, cardiac hypertrophy, fibrosis, and myofibroblast activation.

Main Results:

• Long-term canstatin administration improved survival rates post-MI.
• Canstatin significantly inhibited left ventricular dilatation, dysfunction, and scar thinning.
• It suppressed cardiac hypertrophy, nuclear factor of activated T-cells translocation, interstitial fibrosis, and myofibroblast proliferation in non-infarcted areas.
• Canstatin inhibited TGF-β1-induced differentiation of cardiac fibroblasts into myofibroblasts.

Conclusions:

• Long-term administration of recombinant canstatin demonstrates significant cardioprotective effects in a rat model of MI.
• Canstatin mitigates adverse cardiac remodeling, including hypertrophy and fibrosis, thereby improving cardiac function and survival.
• This study highlights canstatin as a potential therapeutic agent for preventing heart failure after myocardial infarction.